{"nctId":"NCT00828191","briefTitle":"Subcutaneous Progesterone Versus Vaginal Progesterone Tablets for Luteal Phase Support in In Vitro Fertilization (IVF)","startDateStruct":{"date":"2008-12"},"conditions":["In Vitro Fertilization"],"count":800,"armGroups":[{"label":"Progesterone SC","type":"EXPERIMENTAL","interventionNames":["Drug: Progesterone"]},{"label":"Progesterone Tablets","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Progesterone"]}],"interventions":[{"name":"Progesterone","otherNames":[]},{"name":"Progesterone","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patient has given written informed consent;\n* BMI \\< 30 kg/m2;\n* Age 18 - 42 (upon starting COH);\n* \\<3 prior ART cycles (IVF, ICSI and related procedures);\n* Baseline (day 2-3 of cycling) FSH \\<15 IU/L and E2 \\<80 pg/mL;\n* Normal uterine cavity as per recent hysterosalpingogram, sonohysterogram or hysteroscopic exam (i.e. no polyps or protruding submucosal fibroids);\n* Patients must have at least three retrieved oocytes.\n\nExclusion Criteria:\n\n* Intramural uterine fibroids that distort the uterine cavity or polyps \\>1 cm;\n* Stage III or IV endometriosis (no endometriomas);\n* Hydrosalpinges;\n* History of past poor response to COH resulting in canceling ART;\n* Use of thawed/donated oocytes;\n* Use of thawed/donated embryos;\n* Gestational carrier;\n* Patients affected by pathologies associated with any contraindication of being pregnant;\n* Hypersensitivity to study medication;\n* Uncontrolled adrenal or thyroid dysfunction;\n* History of conditions (i.e. toxic shock syndrome) that would contraindicate use of a vaginal progesterone product;\n* History of arterial disease;\n* Patients with hepatic impairment (liver function tests \\> 2x upper limits of normal);\n* Patients with dermatologic disease;\n* Patients with renal impairment (estimated creatinine clearance \\<60 mL/min/1.73 m2);\n* Neoplasias (current) or history of neoplasia that may be responsive to progesterone;\n* High grade cervical dysplasia;\n* History of recurrent pregnancy loss defined as 3 or more spontaneous miscarriages, wherein pregnancy developed to a minimum of a gestational sac on TVUS;\n* Participation in a concurrent clinical trial or in another trial within the past 2 months;\n* Use of concomitant medications that might interfere with the study evaluation;\n* Pre-implantation genetic diagnosis/screening","healthyVolunteers":false,"sex":"FEMALE","minimumAge":"18 Years","maximumAge":"42 Years","stdAges":["ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Ongoing Pregnancy Rate","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"40.8","spread":null},{"groupId":"OG001","value":"43.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Implantation Rate","description":"Implantation rate was defined as the number of gestational sacs divided by the number of embryos transferred (%). This value was calculated for all the patients who had at least one embryo transferred.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"33.2","spread":"42.0"},{"groupId":"OG001","value":"35.1","spread":"40.9"}]}]}]},{"type":"SECONDARY","title":"Delivery Rate","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"40.5","spread":null},{"groupId":"OG001","value":"42.5","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":400},"commonTop":["Headache","Breast pain/tenderness","vaginal hemorrage","Injection site discomfort","Vaginal discharge"]}}}